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boxane A2 (TXA2) may prevent coronary thrombosis and thereby coronaty
obstruction. In this etudy we tested the hypothesis that sodium ozagrel (SO),
a TXA2 synthetase inhibitor, reduces intracoronary platelet deposition and
attenuates proliferative action of smooth muscle cell at sites of endothelial
injuty during primary coronary angioplasty (CA). Ninety-two patients (pts)
sewed with CA for firat acute myocardial infarction (AMI) were divided into
two groups; 44 pts without SO (Gl) and 48 pts with SO (G2). In Gl, only
routine hepatfn and isoaorbide dinitrate were administered during and early
after CA. In G2, in addition to the protocol, SO of 0.4 mg/Kg Intracoronary
bolus injection and of 1.2 mg/Kg intravenously (iv) infusion by 1 hour was
administered during CA, and additional SO of 1.6 mg/Kg iv by 1 hour was in-
fused at 12 hours after CA. Coronary restenosis was evaluated 5 days (lst),
4 weeks (2nd), 4 months (3rd) after CA in all pta. Resu/ts:Acute reocclusion
of infarct-related artery occurred in 2 (4%) of 46 pts with SO and 10 (23%) of
44 pta without SO (p < 0.01).
RD (mm) 6/A DN Post CA (“A) Ist (%) 2nd(“A) 3rd(OA)
G1 2.67+ 0.38 1.1+ 0.5 4.3+ 1.1 24i 9 39&27 48k 25 62&24
G2 2.59+0.34 1.0+0.3 4.2i 0.6 21i 13 27&21* 28+ 22” 47* 29*
RD: reference diameter, WA: balloonto artery ratio, DN: dilationnumbers,*P -= 0.05 vs
GI
While % etenosis was progreesively increased inGl, it was hindered in
G2 even with comparable CA reeults. Corrc/usiorrs:Thefindings indicate that
eodium ozagrel may prevent thrombotic reocdusion, which might attenuate
proliferative restenosis late affer CA. Thus, we conclude that sodium ozagrel
is a potential preventer of acute reocclusion and restenosis in pts with AMI
served with primary coronaty angioplasty.
1947-11I Bolu~magnesiuminfu~i~ni human~i~a~~~~iat*
withpredominantlyunfavorablechangeainplatelet
aggregationandcertainhemostaticfactors
V.L. Serebruany, W.R. Herzog, P.A.Gurbel. UrrionMemorial Hospital, and
The University of Maryland, Baltimore, MD, USA
The purpo$e of thia study was an attempt to extrapolate favorable obser-
vations of the effects of magnesium (Mg) on platelets and hemostasis from
the animal models to humans. We asseased the effect of bolua Mg infusion
on ex vivo platelet aggregation (PA) and certain hemostatic parameters in
healthy volunteers. One gram of Mg was diluted in 50 ml D5W and infused
over 15 minutes. The changes of PA, plasma antithrombin-111(AT-III),Protein
C (PC), total Protein S (PS), fibronectin (Fn), endothelin-1 (ET-l), as well as
the metebolites of thromboxane (Tx) and prostacyclin (PGI)were determined
prior to, and immediately after Mg infueion. SOrum Mg incrOasedfrom 2.1
+ 0.1 at baseline to 3.1 + 0.1 m@dL (p = 0.0002) post infusion and wee
associated with aignificent elevation in ADP- (+19.3Yo); rfstocetin- (+13.6%);
and collagen-induced (+14.27.) PA; increase in AT-III (+10.3Yo),and Tx
(+37.6%). In contract, PS (–20.7%), PC (-11.2%), and ET-1 (-26.3%) were
decreaeed. There were no significant differences in plasma Fn and PGI lev-
els. Acknowledging beneficial effect of Mg on vasoreactivity (diminished ET-1
level), increased platelet aggregability, acquired Protein Canal Protein Sdefi-
ciency, enhanced concentrations of Tx were found contrarily to expectations
based on the animal models. These findings indirectly support the 1S1S4re-
sults, denying clinical advantages of Mg therapy in patients with myocerdial
infarction. This etudy auggests that one must be cautious in drawing clinical
conclusions from the animal models, so as in speculations on the clinical
significance of experimental findings.
Gr-N than Gr-C. Compared to Gr-C, Gr-N showed the greater reduction in
LV volume and the better functional improvement. Conclusion: The intra-
venous N prevents the progression of microvascular damages in AMI and
this prevention seems to provide the better outcomes than repetfusion alone.
“/nNR ALVEDVI ALVESVI ARWM AWMSI
Nicorandil(n = 30) 13# –4,7 + 22.8# -8.4 + 14,6# 1,0 + 1.4# -1,0+ O.S#
Control(n= 30) 33 13.6 + 23.0 7.4 +21,S 0.2 +0.8 –0.5+0.6
#P<0.05 Vscontrol.A = IM vatue – ID value.
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-[ silentversus~ymptomati.~esiduallschaemi.
AtierThrombolysedMyocardialInfarctionin
PatientaRandomizedto MedicalTherapyor
Revascularization
T.T.Nielsen, U.H. Eriksen, P.Grande, J.K. Madsen, K. Saunam~ki,
P,Thayssen, E. Kassia, K. Rasmussen, S. Haunsa, T. Haghfelt, for the
DANAMI Study Group. Skejby University Hoapita/, Denmadr
The aim was to compare the long term benefit of invasive (PTCAand CABG)
versus consqwative treatment strategies in patients thrombolysed for their
first acute myocardial infarction who had symptomatic or silent post-infarction
ischemia.
Patients <70 years old with symptoms <12 hours and no previous AMI,
PTCA or CABG were recruited. To be included pte had to demonstrate.
post-infarction ischaemia: 1. Symptomatic angina pectoris presenting >36
hours after admission during hospital stay or during exercise test before
discharge, and/or 2. ST-deviation during exercise test> 0.1 mV.Two groupe
with post-infarction iachemiawere identified: Angina plua/minus documented
ischemia (n = 441, 44%) and silent ischemia (n = 567, 56%). Endpoints were
unstable angina (UAP), re-AMl, and death. Totally, 503 pts were randomized
to invasive strategy and 505 pts to conservative therapy,
Symptomatic RR
Coneerv. Invasive RR Conaew. Invasive RR
UAP 44.5”/0 27.6”A 0.62” 21.6% 13.2% 0.61”
re-AMl 13.3% 7.2”/a 0.54” 10.1% 5.7”/0 0.57”
Death 6.00/0 4.O”A 0.6S 3.s% 3.60/. 0.93
*p <0.05.
Cone/uaiorr:Compared to a mnservative strategy, “late” invasive treat-
ment almost halved the incidence of non-fatal reinfarction and admisaione
with unstable angina in thrombolysed AMI patients with symptomatic as well
as silent post-infarction ischemia, during a median of 2.4 years follow-up. No
reduction in death was found. Patients with symptomatic had more events
than patients with silent iachemia.
D94712 MicrovascularProtectionwithIntravenousNicorandilAugmentsMyocardialSalvagein
PatientawithAcuteMyocardialInfarction
T. Yoshiaki, L Hiroshi, 1.Kateuomi, N. Nagahiro, T. Shin, F. Kenahi. ,
Sakurabashi Watanabe Has-pital,Osaka, Japan
Experimental studiee documented that pharmacological protection of mi-
crovasculature against ischemic injury augments myooardial salvage.
In this study, we examined whether intravenous K+ channel opener (nico-
randil (N)) can prevent microvascular damage and whether this prevention
leads to the better functional improvement in 60 patients with reperfused
AMI. We divided the patients into 2 groups; N group (n = 30) and control (C)
group (n= 30). Intravenous N (4 mg bolus and 6 mg/h) was initiated >30 min
before reperfusion and wae Iaetedat least 24 hours, followed by oral admin-
istration (15 mg/day). We performed myocerdial contrast echocardiography
after reperfusion and determined the presence or absence of substantial no
reflow phenomenon (NR). We calculated the differences in LVvolumes (ml),
regional wall motion (RWM, SD/chord) and average wall motion score in
the infarct zone (WMSI, dye/akinesia = 3 to normal = O)between baseline
and follow-up (3 months) studies. F?eau/ts:Frequency of NR was lower in
1948-141 Tento14 YearFollow-Upof thelnteruniversity
CardiologyInstituteTrial:ImprovadLong-Term
SurvivalinAcuteMyocardialInfarctionPatients
TreatedWithEarlyThrombolyticTherapy
A.C.P. Maas, R.T.van Domburg, J. Vos, J.W. Deckers, F.Vermeer,
W.J. Remme, O. Kamp, V. Manger Cata, M.L. Simoons. Rotterdam,
Maastricht, Amsterdam and Leiden, The Netherlands
BackgrourrcVMethoda:In order to assess the long-term outcome of early
thrombolytic therapy in acute myocardial infarction (Ml), patients who partic-
ipated in the ICIN trial (n = 533) were followed-up for 10 to 14 years. Life
status was asseased and major cardiac events (re-Ml, PTCA, CABG) were
checked by hospital record review and enquiries to the general practitioner.
Resu/ts: At a median follow-up time of 11 years, survival was improved
significantly (p e 0.02) in patients (n = 269) treated with intracomnary strep-
tokinase (SK) as compared to conventionally treated (CT) patients (n = 264).
Suwival at 1, 5 and 10 yeare waa 91%, 61% and 69% in the SK group
and 64%, 71Y0and 59Y0in the CT group. Ten year freedom from death/re-
M1/CABGiPTCAwas 29% and 32% for SK and CT, respectively (p = ne).
Analysis of hospital survivor data revealed LVfunotion at discharge to be the
strongest independent predictor of long-term survival, followed by the extent
